Evidence map›Paper›PMID 38913557›Full record

ArticleUrology practice2024

Surgical Outcomes and Genomic Insights of Nonclear Cell Renal Cell Carcinoma With Synchronous and Metachronous Nodal Disease.

Lennert Eismann, Mark Zucker, Mark T Dawidek, Stephen W Reese, Lina Posada Calderon, Andreas Aulitzky, Christian G Stief, Jonathan A Coleman, Ritesh R Kotecha, Maria Carlo and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Lennert EismannUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Mark ZuckerComputational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Mark T DawidekUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Stephen W ReeseUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Lina Posada CalderonUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Andreas AulitzkyUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Christian G StiefDepartment of Urology, University Hospital Munich, LMU, Munich, Germany.
Jonathan A ColemanUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Ritesh R KotechaGenitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Maria CarloGenitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Yingbei ChenGenitourinary Pathology, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Ed ReznikDepartment of Urology, New York Presbyterian-Weill Cornell Medicine, New York, New York.
Paul RussoUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
A Ari HakimiUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

introductionOncological outcomes in patients with nonclear cell renal cell carcinoma (non-ccRCC) treated with surgery for locoregional nodal disease (ND) remain incompletely characterized. The objective was to investigate the characteristics and outcomes of non-ccRCC patients treated with lymph node dissection (LND) and salvage-LND (S-LND).

methodsA total of 1627 patients underwent nephrectomy for nonmetastatic non-ccRCC at Memorial Sloan Kettering Cancer Center between 2007 and 2023. Histology was grouped as papillary, chromophobe, unclassified, and rare subtypes. Retrospective evaluation identified 2.5% (n = 40) of patients with nodal disease at time of nephrectomy (synchronous-ND) and 1.1% (n = 18) with metachronous nodal disease limited to the retroperitoneum (metachronous-ND). Patients' demographics and tumor characteristics were recorded and evaluated by univariate and multivariate cox regression models. Recurrence-free survival (RFS) and overall survival (OS) were estimated by the Kaplan-Meier method. Patients who underwent tumor DNA sequencing during their clinical course were considered for genomic analysis.

resultsOS trended toward longer in metachronous-ND (51 vs 105 months;

conclusionsPatients with metachronous-ND tend to have prolonged OS compared to synchronous-ND, but a substantial portion of patients with synchronous-ND still enter a durable disease-free state following LND. S-LND can likewise provide long-term survival, particularly in patients with longer time to metachronous nodal recurrence. Synchronous-ND was associated with

Indexed as

Carcinoma, Renal CellKidney NeoplasmsLymph Node ExcisionNephrectomyAdultAgedFemaleGenomicsHumansLymphatic MetastasisMaleMiddle AgedNeoplasms, Multiple PrimaryNeoplasms, Second PrimaryRetrospective StudiesTreatment Outcomelymph node excisionnephrectomyrenal cell carcinoma

Identifiers

PMID38913557
PMCPMC11335441

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.